Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Optimi Health Corp.Bullish
Optimi Health has completed the production of its latest MDMA finished drug product batch. This supply is designated for a proposed Phase 3 clinical trial in Canada, a clinical trial in Israel in partnership with MAPS, and commercial exports to Australia.…more
Optimi Health Corp.
Optimi Health Corp. will participate in the ThinkEquity Conference held in New York City on October 15, 2026. Management will present a corporate overview and be available for one-on-one meetings with registered investors.…more
Optimi Health Corp.
This is a SCHEDULE 13G/A filing regarding the beneficial ownership of Optimi Health Corp. shares by YA II PN, Ltd. The reporting entity has updated its position in the company through this filing.…more
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
Optimi Health Completes MDMA Production for Clinical and Commercial Use…more
Optimi Health has completed a production batch of MDMA to support its upcoming Phase 3 PTSD trial in Canada and commercial supply in Australia. The company's future valuation will depend on the progress of these clinical programs and sustained commercial demand.…more
●●●●●●●● ●●●●● ●●●●●●
Optimi Health announced its participation in the upcoming ThinkEquity Conference in New York on October 15. The event will feature a corporate presentation and one-on-one meetings with investors, though no specific financial or contract results were disclosed.…more
●●●●●●●● ●●●●● ●●●●●●
Optimi Health has appointed finance executive Melanie Pump to its Board of Directors to leverage her expertise in growth-oriented companies. This leadership change is a corporate governance update with no immediate material impact on the stock price.…more
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.